Research Article: Dermatological adverse events in Chinese prostate cancer patients treated with the androgen receptor inhibitor apalutamide
Abstract:
Background: Apalutamide, an androgen receptor inhibitor, has shown good efficacy in treating prostate cancer (PCa). However, dermatological adverse events (dAEs) are common and threatening, and relevant studies in China are limited.
No summary available.